000 | 04546nam a22006737a 4500 | ||
---|---|---|---|
008 | 130913s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies | ||
022 | _a0002-9149 | ||
040 | _aOvid MEDLINE(R) | ||
099 | _a22341925 | ||
245 | _aSafety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. | ||
251 | _aAmerican Journal of Cardiology. 109(9):1288-94, 2012 May 1. | ||
252 | _aAm J Cardiol. 109(9):1288-94, 2012 May 1. | ||
253 | _aThe American journal of cardiology | ||
260 | _c2012 | ||
260 | _fFY2012 | ||
266 | _d2013-09-17 | ||
501 | _aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006 | ||
520 | _aData from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. However, limited data are available comparing the XIENCE V to the first-generation CYPHER sirolimus-eluting stent. This study aimed to assess the long-term safety and clinical efficacy of the XIENCE V everolimus-eluting stent compared to first-generation stents in an unselected patient population. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents from 2003 to 2009 at our institution. The patients were followed up for >=1 year after the index procedure. The baseline characteristics were generally comparable among the 3 groups, with the exception of a significantly greater prevalence of diabetes mellitus, systemic hypertension, and a history of angioplasty and coronary bypass surgery among the XIENCE patients. The XIENCE patients also had a twofold greater rate of type C lesions. One-year follow-up data were available for 82% of the patients. The 1-year major adverse cardiovascular events rate was 9.3% for the XIENCE stent versus 9.8% for the CYPHER stent and 11.5% for the TAXUS stent (p = 0.11). Mortality was lower in the XIENCE group than in the CYPHER and TAXUS groups (3.6% vs 4.9% vs 7.2%, respectively, p <0.001), and target lesion revascularization was similar (5.9% vs 5.2% vs 5.6%, respectively; p = 0.34). Stent thrombosis was lower in the XIENCE patients (0.2% vs 1.2% vs 0.7%, p = 0.007). In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The XIENCE V failed to demonstrate superiority for overall major adverse cardiovascular events, Q-wave myocardial infarction, and revascularization rates. Copyright 2012 Elsevier Inc. All rights reserved. | ||
546 | _aEnglish | ||
650 |
_a*Angioplasty, Balloon, Coronary/mt [Methods] _9952 |
||
650 |
_a*Coronary Artery Disease/th [Therapy] _9171 |
||
650 |
_a*Drug-Eluting Stents _9525 |
||
650 |
_a*Sirolimus/aa [Analogs & Derivatives] _9674 |
||
650 |
_aAged _92 |
||
650 |
_aAntineoplastic Agents, Phytogenic/pd [Pharmacology] _9966 |
||
650 |
_aCoronary Angiography _990 |
||
650 |
_aCoronary Artery Disease/ra [Radiography] _991 |
||
650 |
_aCoronary Restenosis/pc [Prevention & Control] _9967 |
||
650 |
_aFemale _97 |
||
650 |
_aFollow-Up Studies _9968 |
||
650 |
_aHumans _911 |
||
650 |
_aImmunosuppressive Agents/pd [Pharmacology] _9969 |
||
650 |
_aMale _914 |
||
650 |
_aMiddle Aged _915 |
||
650 |
_aPaclitaxel _9970 |
||
650 |
_aProsthesis Design _981 |
||
650 |
_aRetrospective Studies _946 |
||
650 |
_aSirolimus/pd [Pharmacology] _9971 |
||
650 |
_aTreatment Outcome _918 |
||
651 | _aMedStar Heart & Vascular Institute | ||
657 | _aComparative Study | ||
657 | _aJournal Article | ||
657 | _aRandomized Controlled Trial | ||
657 | _aResearch Support, Non-U.S. Gov't | ||
700 |
_aBarbash, Israel M _9965 |
||
700 |
_aBen-Dor, Itsik _922 |
||
700 |
_aDvir, Danny _923 |
||
700 |
_aKent, Kenneth M _9135 |
||
700 |
_aMaluenda, Gabriel _9286 |
||
700 |
_aPichard, Augusto D _927 |
||
700 |
_aSatler, Lowell F _929 |
||
700 |
_aSuddath, William O _9139 |
||
700 |
_aTorguson, Rebecca _9140 |
||
700 |
_aWaksman, Ron _930 |
||
700 |
_aXue, Zhenyi _9141 |
||
790 | _aBarbash IM, Ben-Dor I, Dvir D, Kent KM, Maluenda G, Pichard AD, Satler LF, Suddath WO, Torguson R, Waksman R, Xue Z | ||
856 |
_uhttp://dx.doi.org/10.1016/j.amjcard.2011.12.019 _zhttp://dx.doi.org/10.1016/j.amjcard.2011.12.019 |
||
942 |
_cART _2z _dArticle |
||
999 |
_c1397 _d1397 |